
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed Inc. is experiencing robust growth, highlighted by a 98% increase in third-quarter revenue, reaching $13.1 million, driven by a substantial rise in the number of surgeon users, which grew by over 70% year-over-year. The adoption of its AI-enabled personalized spine surgery solutions in a significant $13.4 billion US lumbar fusion market, along with strategic plans to expand into the cervical market by 2026, indicates a strong trajectory for future earnings and overall market penetration. Additionally, the company has achieved a gross margin of 75.9%, exceeding forecasts, as a result of lower contract manufacturing costs and inventory reserve expense reductions, suggesting enhanced operational efficiency.
Bears say
Carlsmed Inc faces a negative outlook largely due to projected revenue shortfalls, with estimates for cervical revenue in FY26 at $2.9 million, which is below prior estimates and reflects challenges in market adoption. The company's potential for success is hindered by several factors, including sluggish uptake of their aprevo technology by new surgeons, anticipated slower growth rates in the overall spine market, and increasing operational expenses. Additionally, competitive pressure from larger players with more diverse portfolios, coupled with adverse reimbursement changes affecting pricing strategies, further compounds the risks associated with Carlsmed's financial stability and market share growth.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares